Review

Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Therapy

Junli Ma, Qihang Zhou and Houkai Li*

Center for Traditional Chinese Medicine and Systems Biology, Institute for Interdisciplinary Medicine Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;

*Correspondence: houkai1976@126.com; Tel.: +86-21-5132-2729

Abstract: Gut microbiota play critical roles in development of obese-related metabolic diseases such as nonalcoholic fatty liver disease (NAFLD), type 2 diabetes, and insulin resistance, which highlighted the potential of gut microbiota-targeted therapies on these diseases. There are various ways that can manipulate gut microbiota including probiotics, prebiotics, synbiotics, antibiotics and some active components from herbal medicines. In this review, we first reviewed the main roles of gut microbiota in mediating the development of NAFLD, and the advances in gut microbiota-targeted therapies on NAFLD in both the experimental and clinical studies, as well as the conclusions on the prospect of gut microbiota-targeted therapies in the future.

Keywords: Gut microbiota; obesity; insulin resistance, NAFLD; probiotic; prebiotic; symbiotic;

1. Introduction

The mammalian gastrointestinal tract is the main site for commensal bacteria. There are over $10^{14}$ microorganisms inside human body [1], which play important roles in maintaining human health [2]. The abundance and composition of gut microbiota are highly variable in the context of different conditions contributing to development of various diseases [3, 4]. In recent years, a huge number of studies have revealed the critical roles of gut microbiota in affecting development of metabolic diseases including type 1 and 2 diabetes [5, 6], obesity [7-10], cardiovascular disease[11-13], and chronic liver diseases[14].

Nonalcoholic fatty liver disease (NAFLD) is a spectrum of chronic liver diseases including simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [9]. NAFLD is the most common chronic liver disease due to the prevalence of obesity worldwide[15]. In addition to the well-established “two-hit” theory [16], the alteration of gut microbiota also promotes the development of NAFLD by mediating processes of inflammation, insulin resistance, bile acids and choline metabolism[17, 18]. As a result, the elucidation on the roles of gut microbiota in NAFLD highlights the significance of gut microbiota-targeted therapies for NAFLD [19, 20]. There are various ways in manipulating gut microbiota including probiotics, prebiotics, synbiotics, antibiotics and some active components from herbal medicines.

In this review, we retrieved the publications on the topics of gut microbiota and NAFLD mainly published within the past 10 years through Pubmed. Based on all of the publications available, we first reviewed the main roles of gut microbiota in mediating NAFLD formation. Then, we discussed the status of gut microbiota-targeted therapies in NAFLD with both the experimental and clinical evidence, and made conclusions on the therapeutic potential by manipulating gut microbiota in the future.

2. Roles of gut microbiota in NAFLD development

Obesity is the common ground of most metabolic diseases. Gut microbiota play critical roles in the development of obesity and obese-related metabolic diseases[21] by producing microbial metabolites like short-chain fatty acids (SCFAs) that regulate host energy harvest[22, 23], or...
modulating signaling pathways of host energy metabolism[24]. Study reveals gut microbiota
promote the intestinal absorption of monosaccharides accelerating the de novo hepatic lipogenesis
and suppressing fasting-induced adipocyte factor resulting in the accumulation of triglycerides in
adipocytes [25]. More evidence of gut microbiota in affecting host energy metabolism has been
acquired in numerous studies [25-27].

Insulin resistance is a basic pathophysiological process of metabolic diseases [28, 29]. In
NAFLD, insulin resistance accelerates the fat accumulation and inflammation in hepatocytes[30].
The enhanced inflammation and insulin resistance forms a “vicious cycle” deteriorating the
development of NAFLD. The gut epithelium is a natural barrier for preventing translocation of
detrimental bacteria and harmful elements into circulation. NASH patients are typically
characterized with small intestine bacterial overgrowth (SIBO) that may impair the intestinal tight
junction and subsequently increase intestinal permeability. SIBO also induces hepatic expression of
TLR4 and release of interleukin (IL)-8 that stimulates inflammatory reaction. The term “metabolic
endotoxemia” was coined because of increased lipopolysaccharide (LPS) levels in circulation of
metabolic diseases [31], in which LPS combines with LBP (LPS binding protein) and then binds to
the CD14/TLR-4 complex triggering an inflammatory reaction and insulin resistance [32-34].
Therefore, the gut dysbiosis is causative for enhanced secretion of LPS and its mediated
inflammation in NAFLD development.

Choline not only is an indispensable component of cell membrane phospholipids, but also plays
important role in lipids metabolism. Choline facilitates the lipids transport in hepatocytes and
prevents the abnormal accumulation of lipids in liver, while choline deficiency usually leads to
hepatic steatosis [35, 36]. Gut microbiota also involve in choline metabolism by converting it into
toxic dimethylamine and trimethylamine, which are transported to liver and converted into
trimethylamine oxide (TMAO) that causes liver inflammation and damage[37]. The increased
production of TMAO is also the culprit for cardiovascular disease [37-39]. On the other hand, the
content of dietary choline influences the composition and abundance of gut microbiota that are
associated with the development of NAFLD [40]. The close relationship between gut microbiota and
choline metabolism provides important rationale for gut microbiota-targeted therapy for NAFLD.

Bile acids are synthesized from cholesterol with a wide range of physiological functions. Bile
acids can not only facilitate digestion and absorption of fat-soluble food, but also preserve the
intestinal barrier and preventing bacterial translocation [41, 42]. Moreover, bile acids could function
as signaling molecules that modulate the balance of bile acids metabolism by activating farnesoid X
receptor (FXR) and G protein-coupled receptor (TGR5)[43-46]. Studies reveal that antibiotics could
attenuate the high-fat diet-induced NAFLD development by altering the composition of bile acids
and inhibiting FXR signaling pathway, whereas mice with intestine-specific Fxr disruption have
reduced triglyceride accumulation in the liver compared with control mice [47]. Bile acids usually
have strong anti-microbial property and gut microbiota can influence the homeostasis of bile acids
pool by deconjugating and metabolizing the primary bile acids into secondary bile acids in intestinal
tract, which are involved in modulating lipids and energy metabolism pathways during NAFLD
formation[44]. The crosstalk between gut microbiota and bile acids provides fundamental evidence
for gut microbiota-targeted therapy of NAFLD. A schematic view on the roles of gut microbiota on
NAFLD formation was summarized in Figure 1.
3. Gut microbiota-targeted therapies on NAFLD

NAFLD is common with the prevalence of obesity currently, however, clinical therapeutic options are still very scarce in respect to the safety, effectiveness and patient compliance [61]. As a result, the intricate relationship between gut microbiota and NAFLD opens up a new window for seeking effective and safe therapies on NAFLD by restoring gut homeostasis of NAFLD patients with various ways.

3.1 Gut microbiota-targeted therapy with probiotic

Figure 1 Schematic view on roles of gut microbiota in NAFLD [2, 48-60].
Probiotics are a collection of bacteria with a wide range of beneficial effects on host metabolism [2, 62]. Bacteria of *Lactobacillus, Bifidobacterium* and *Satreptococcus* are most frequently used probiotics that can inhibit expansion of gram-negative pathogenic bacteria [63]. Okubo H et al. investigated the effects of *Lactobacillus caseistrain Shirota* (LcS) on methionine-choline-deficient (MCD) diet-induced NASH mice [64]. They found that MCD diet feeding resulted in significant reduction in lactic acid bacteria (*Bifidobacterium* and *Lactobacillus*) in feces, but were increased by LcS supplement. Moreover, LcS supplement dramatically improved the symptoms of NASH induced by MCD such as hepatic histology, serum parameters (TG, TC, ALT), as well as the altered expression of hepatic genes and proteins (the mRNA levels of α-SMA and TIMP-1). Meanwhile, metabolic beneficial effects of LcS supplement were observed in high-fat diet (HFD)-induced and genetic *db/db* obese mice, in which LcS supplement significantly improved insulin resistance and lowered plasma levels of LBP [65]. Study revealed that LcS treatment protected against the fructose-induced NAFLD by suppressing the activation of TLR4 signaling cascade in liver [66].

Accordingly, the beneficial effect of LcS in metabolic diseases is due to the improvement of metabolic endotoxaemia. *Lactobacillus* is a genus of gram-positive bacteria which can convert sugars into lactic acid. Bacteria from *Lactobacillus* genus have been trialed as probiotics in studies [67-69]. Sohn W et al. investigated the effects of *Lactobacillus paracasei* (*L.paracasei*) on NASH patients [70], they found that *L.paracasei* administration lowered inflammatory cytokines in NASH patients, however, probiotics with single species of *Lactobacillus* bacteria did not show benefit in patients with irritable bowel syndrome or Crohn’s disease[71, 72]. Meanwhile, the beneficial effects of *Lactobacillus plantarum* probiotics were investigated on NAFLD models such as *L. plantarumMA2*, *L.plantarumA7* and *L.plantarmNCU116*. Results showed that either *L. plantarumA7* or *L. plantarumMA2* was effective in lowering serum lipids [73] [74], while *L.plantarmNCU116* improved liver function and decreased hepatic fat accumulation as well [75]. Similar effect was observed with *L.rhamnosus* supplementation on NAFLD model. Probiotic of *L. rhamnosus* GG (LGG) protected mice from NAFLD by increasing the abundance of beneficial bacteria, improving gut barrier function and attenuating hepatic inflammation [76], as well as the cholesterol-lowering effect through inhibition of FXR and FGF15 signaling pathway [77]. In addition, several other species of *Lactobacilli* bacteria have shown potential in NAFLD prevention including *L. johnsonii* BS15 [78], *L.reuteri* GMNL-263 [79], *L. gasseri BNR17* [80].

*Bifidobacterium* (Bif) belongs to *Bifidobacteria* bacteria genera in mammalian gastrointestinal tract, which is a frequently used probiotic [81-83]. Supplement of Bif significantly improved visceral fat accumulation and insulin sensitivity in HFD fed rats [84]. Administration of *Bifidobacterium pseudocatenulatum* CECT 7765 could reduce serum cholesterol, triglyceride, and improved glucose tolerance in obese mice [85]. It is proposed that probiotic of Bif is superior to *Lactobacillus acidophilus* in reducing hepatic fat accumulation [86]. Compared to probiotic with single strain of bacteria, VSL#3 is a mixed probiotic with eight types of bacteria (*Bifidobacteria* [B. breve, B. longum, B.infantis], *Streptococcus thermophilus*, *L. plantarum*, *L. acidophilus*, *L. paracasei* and *L. delbrueckii* subsp. *bulgaricus*) which has shown great potential in treatment of various diseases [87-91]. Experimental evidence have indicated that VSL#3 could attenuate inflammation via modulating NF-kB pathway [92], reduce hepatic fat accumulation and ALT levels [93], improve insulin sensitivity in NAFLD models[94], as well as prevention against liver fibrosis in NASH patients[95]. The probiotic with combined bacteria (LGG, *Lactobacillus plantarum* WCFS1 and *Bacillus* from *cassia obtusifolia* L.) was effective in reducing blood lipid levels and improving insulin resistance in NAFLD rats [96]. Meanwhile, supplementation of combined probiotic (*Bifidobacterium infantis*, *Lactobacillus acidophilus* and *Bacillus cereus*) could improve gut dysbiosis and liver function via suppression on LPS/TLR4 signaling pathway [97]. Kim DH et al. found that consumption of kefir (a probiotic beverage containing over 50 species of lactic acid bacteria and yeast) prevented obesity and NAFLD formation by restoring gut microbiota and enhancing fatty acid oxidation in HFD-fed mice[98]. Further evidence of beneficial effects on NAFLD prevention has been acquired in many studies by administering probiotics with mixed bacteria [99-101]. In addition to the direct impacts on the
composition of gut microbiota, the beneficial effects of probiotics on NAFLD are also associated with their metabolic activities [53]. It has been reported that probiotic of MIYAIRI 588—a butyrate-producing bacteria decreased accumulation of lipid droplets in HFD-induced NAFLD models and improved insulin resistance[102], reduced hepatic lipids and serum endotoxin levels in choline-deficient/L-amino acid-defined diet induced NAFLD models [103], which may be associated with the stimulation on expression of AMPK and AKT proteins, and lipogenesis- or lipolysis-related proteins.

Currently, although the beneficial effects of probiotics were mainly acquired in experimental studies, some consistent results have also been observed in clinic. Alisi et al. compared the therapeutic effects of VSL#3 in a randomized double-blind RCT study in obese children with biopsy-proven NAFLD. They found that 4-month supplement of VSL#3 significantly improved the liver function and increased GLP-1/ aGLP1 levels suggesting the effects of VSL#3 might be GLP-1-dependent [104]. Consistent effects were also observed on obese children with NAFLD by administering probiotics such as Lactobacillus rhamnosus strain GG [105] and mixed bacteria of Lactobacillus bulgaricus and Streptococcus thermophilus [106]. Sepideh, A et al. investigated the effects of a multistrain probiotic supplementation in NAFLD patients in a RCT study, and the results showed dramatic improvement in insulin sensitivity and inflammation [107]. Moreover, synergistic effects were also observed by combining probiotics with chemical drugs such as metformin in NASH and statins in NAFLD therapy [108, 109], which highlights the great potential of clinical application of probiotics either alone or combined with other drugs. Nevertheless, the clinical efficacy of probiotics still needs further validation in well-designed studies with larger scale of participants. Solga et al. observed that 4 month of probiotics supplement not only did not reduce hepatic steatosis, but increased fat accumulation in liver of 4 patients [110]. In 2010, Andreasen AS et al. conducted a randomized-double-blinded research on effects of Lactobacillus NCFM on insulin sensitivity and the systemic inflammation [111]. They found that insulin sensitivity was improved in probiotic group, but not in placebo group, and no differences in systemic inflammation in both groups. Meanwhile, another study indicated that 8-week probiotic supplement did not improve total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, Triglycerides (TG), TG/LDL and LDL/HDL ratios in diabetic patients [112]. Additionally, supplement of Lactobacillus acidophilus did not improve the levels of plasma lipids in volunteers with elevated cholesterol in a double-blind placebo-controlled study [113]. A detailed summary of gut microbiota-targeted therapies on NAFLD with probiotics were provided in Table 1.

3.2 Gut microbiota-targeted therapy with prebiotic

Prebiotics are indigestible food ingredients with beneficial effect by selectively stimulating the growth and/or activity of “good” and suppressing “bad” bacteria resident in the colon [114], or defined as fermented ingredient that allows changes both in the composition and/or activity in the gastrointestinal microflora conferring benefits upon host well-being and health [115] [116]. Evidence suggested that prebiotics supplement prevented NAFLD development in both experimental and clinical studies [117, 118].

In 2009, Cani et al. found that prebiotic of oligofructose (a mixture of fermentable dietary fibers) decreased plasma LPS and cytokines levels, and hepatic expression of inflammatory and oxidative stress markers in obese mice, as well as improvement in intestinal permeability and production of GLP-2[119]. In MCD diet-induced steatohepatitis mice model, dietary fructooligosaccharides (FOS) supplement attenuated the extent of steatohepatitis by restoring the homeostasis of gut microbiota and intestinal epithelial barrier function [120]. Pachikian, B.D.et al. reported that FOS supplement reduced hepatic triglyceride accumulation in n-3 PUFA-depleted diet-induced NAFLD model by altering microbiota composition and increasing production of GLP-1[121]. Meanwhile, FOS supplement stimulated fatty acid oxidation by activating peroxisome proliferator-activated receptor-alpha (PPAR-α) and reduced cholesterol accumulation by inhibiting SREBP-2 in liver without affecting SREBP-1 expression and activity [121, 122]. Lactulose is a prebiotic that promotes the growth of lactic acid bacteria and Bifidobacteria [123]. A study indicated that Lactulose treatment
decreased the hepatic inflammation and serum endotoxin levels in rats with steatohepatitis [124].

Chitin–glucan (CG) is another type of prebiotic from fungal source. Neyrinck AM et al. investigated the function of CG in HFD-induced obese mice and found CG treatment decreased body weight gain, improved glucose intolerance and hepatic triglyceride accumulation by restoring bacteria of clostridial cluster XIVa [125].

The combination of prebiotic with natural components will yield more benefits than itself. For example, combined therapy of isomalt-oligosaccharides (IMOs) with lycopene (an antioxidant) prevented body weight gain, enhanced adipose tissue fat mobilization and improved insulin resistance and metabolic endotoxemia in HFD-induced NAFLD mice. The observed effects were associated with their modulation on microbial production of SCFAs [126].

In the clinic, prebiotics have also been tested for their benefits in various diseases [127-131]. Oligofructose (OFS), an inulin-type fructans, were added to diet for NASH patients in a pilot randomized double-blind study [118]. Their results showed that OFS supplement decreased serum ALT and AST levels significantly. Prebiotics of mixed galacto-oligosaccharides and fructo-oligosaccharides (9:1) stimulated the abundance of *Bifidobacteria* bacteria in infants [132]. Similarly, administration of prebiotic inulin and oligofructose (50:50 in mixture) increased abundance of *Bifidobacterium* and *Faecalibacterium prausnitzii*, which negatively correlated with serum LPS levels [133]. Prebiotics have shown great potential in prevention of obesity and NAFLD development by lowering the permeability of intestinal wall, attenuating metabolic endotoxemia, and reducing the accumulation of fat [134]. The gut microbiota-targeted therapies with prebiotics were summarized in Table 2.

### 3.3 Gut microbiota-targeted therapy with synbiotic

Synbiotics are the combination of probiotics and prebiotics [135]. Synbiotics usually produce benefits by selectively stimulating the growth and/or activating the metabolism of health-promoting bacteria[136]. Administration of synbiotic containing *Lactobacillus paracasei* B21060 plus arabinogalactan and fructooligosaccharides attenuated hepatic inflammation and increased expression of nuclear PPARs and their targeted genes in HFD-induced NAFLD rats [137]. Synbiotics have shown various benefits in metabolic diseases such as improvement of IR, glucose control, and inflammatory cytokines synthesis [138-140].

In the clinic, the therapeutic effect of a synbiotic containing seven probiotics and oligofructose was evaluated on patients with NAFLD in a double-blind RCT. The results showed that synbiotic therapy significantly decreased ALT levels [141]. Malaguarnera et al. observed that combination of synbiotic (*B. longum* and Fos) and lifestyle intervention in NASH patients resulted in much more improvement compared to lifestyle intervention alone including reduction of serum TNFα, CRP, endotoxin and AST levels, improvement in HOMA-IR and extent of NASH activity index[142]. Synbiotic therapy showed improvement in levels of fasting blood glucose, TG and inflammatory cytokines in both obese and lean NAFLD patients [143,144]. Therefore, synbiotic is one of the promising gut microbiota-targeted interventions on NAFLD prevention or therapy, nevertheless, more clinical validations are also needed. A summarized gut microbiota-targeted therapy on NAFLD with synbiotics was provided in Table 3.

### 3.4 Gut microbiota-targeted therapies with other approaches

In addition to probiotic/prebioticsynbiotic, gut microbiota-targeted interventions have also been investigated with other approaches. Butyrate belongs to SCFAs and is an important gut microbial metabolite derived from fermentation of nondigestible polysaccharides. Butyrate has a critical role in affecting metabolic diseases development through a variety of ways including modulation on energy harvest, hepatic lipogenesis and gluconeogenesis, adipokine signaling in adipocytes, intestinal permeability and appetite regulation in the brain[145, 146]. Administration of sodium butyrate alleviated inflammation and fat accumulation in HFD-induced NAFLD mice by increasing the abundances of the beneficial bacteria *Christensenellaceae, Blautia* and *Lactobacillus* [147]. Therefore, appropriate approaches such as engineered bacteria could be developed to enhance the
production of beneficial gut microbial metabolites (i.e., butyrate) or intervention with chemical drugs to promote the proliferation of “good” bacteria, and suppress the “bad” ones.

Antibiotics are frequently used in the clinic, while their disruption on gut microbial homeostasis is a double-edged sword [148]. On one hand, short-term application of antibiotic can result in long-lasting impacts on host metabolism. On the other hand, administration of some kinds of antibiotics may attenuate diseases. For example, oral administration of cidomycin increased the small intestine transit rate and lowered serum ALT, AST and TNF-α levels in NASH rats suggesting the potential of cidomycin in alleviating the severity of NASH by intervening gut microbiota [149]. In the clinic, administration of rifaximin could decrease the circulating endotoxin and ALT levels in patients with NAFLD [150]. Although the improvement in NAFLD, especially in NASH by short-term administration of antibiotic is observed (i.e., rifaximin), the long-term application of antibiotics is not encouraged because of probable side effects [151]. Nevertheless, the changes of gut microbiota resulted from antibiotics could provide important evidence for exploring alternative ways to modulate gut microbiota in disease therapy.

Compared to antibiotics, some ingredients from herbal medicines have shown more prospects on gut microbiota modulation with minor side effects [152, 153]. Berberine is a typical herbal component with potent antibacterial activity, especially bacteria in intestinal tract because berberine can hardly be absorbed in gut [154]. Currently, increasing evidence has confirmed the therapeutic effect of berberine on metabolic diseases including obesity, NAFLD, and type 2 diabetes via modulation on gut microbiota [155-157]. It has been revealed that berberine administration restored the relative abundance of Bifidobacteria and the ratio of Bacteroidetes/Firmicutes in HFD-induced NASH mice resulting in significant reduction in body weight, serum levels of lipids, glucose, insulin and inflammatory cytokines [158, 159]. TSG (2', 3', 4', 5'-tetrahydroxy-stilbene-2-O-β-D-glucoside) is an active component from Traditional Chinese Medicine (TCM) Polygonum multiflorum Thunb, which has shown significant effect on NAFLD prevention by modulating gut microbiota, improving the intestinal mucosal barrier and suppressing the expression of NF-κB [160]. Resveratrol is a natural polyphenol with anti-oxidative activity [161]. Recent studies showed resveratrol was also effective in preventing metabolic diseases such as obesity and NASH by regulating gut microbiota [162]. In addition to the individual component from herbal medicines, recent investigations revealed that the efficacy of some TCM formula was associated with the modulation on gut microbiota. For example, Qushi Huayu Fang (a mixture of five herbs including Artemisia capillaries Thunb, Gardenia jasminoides Ellis, Fallopia japonica, Curcuma longa L., and Hypericum japonicum Thunb) is an ancient TCM formula which has been used for NAFLD treatment. Recent studies showed that administration of Qushi Huayu Decoction (QHD) significantly decreased body weight, alleviated hepatic steatosis, and reduced the content of TG and free fatty acids in liver in HFD-induced NAFLD rats. It showed that the QHD-treated group harbored significantly different gut microbiota from that of model rats, and the bacterial profiles of NAFLD rats could be modulated by the QHD [163, 164]. Recently, the anti-obesity property of daesiho-tang (DSHT) was also investigated. It was found that DSHT treatment significantly reduced serum TC and TG and hepatic fat accumulation that were associated with the regulation on abundance of gut microbiota [165]. Although the mechanisms underlying TCM therapy are extremely complicated and largely unknown, gut microbiota was supposed to be an important target for many TCM formulas because many kinds of chemicals derived from TCM are unabsorbable. Those unabsorbed chemicals in TCM can influence gut microbiota directly or be metabolized into absorbable or active form by gut microbiota. A summary of gut microbiota-targeted therapies on NAFLD with other approaches were provided in Table 4.

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Main effects</th>
<th>Experimental Models</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Probiotic</td>
<td>Effect</td>
<td>Condition and Disease Model</td>
<td>Reference</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Lactobacillus (LcS)</td>
<td>Suppressing NASH development</td>
<td>MCD diet-induced NASH in mice</td>
<td>[64]</td>
</tr>
<tr>
<td></td>
<td>Improving insulin resistance and glucose intolerance</td>
<td>Diet-induced obesity (DIO) mice</td>
<td>[65]</td>
</tr>
<tr>
<td></td>
<td>Protecting against the onset of fructose-induced NAFLD</td>
<td>Fructose-induced NAFLD in mice</td>
<td>[66]</td>
</tr>
<tr>
<td>L.paracasei</td>
<td>Attenuating hepatic steatosis</td>
<td>(HF+10% fructose diet)-induced NASH in mice</td>
<td>[70]</td>
</tr>
<tr>
<td>L. plantarum A7</td>
<td>Lowering serum lipid, TC and TG levels</td>
<td>High cholesterol diet fed rats</td>
<td>[73]</td>
</tr>
<tr>
<td>L. plantarum MA2</td>
<td>Lowering serum TC, TG and lowdensity lipoprotein cholesterol</td>
<td>Cholesterol-enriched diet fed rats</td>
<td>[74]</td>
</tr>
<tr>
<td>L. plantarum NCU116</td>
<td>Improving liver function, oxidative stress and lipid metabolism</td>
<td>HFD-induced NAFLD in rats</td>
<td>[75]</td>
</tr>
<tr>
<td>Lactobacillus rhamnosus GG (LGG)</td>
<td>Protecting mice from NAFLD attenuated liver inflammation and steatosis</td>
<td>High-fructose diet induced NAFLD in mice</td>
<td>[76]</td>
</tr>
<tr>
<td></td>
<td>Improving NAFLD</td>
<td>HFD-induced NAFLD in rats</td>
<td>[82]</td>
</tr>
<tr>
<td></td>
<td>An improvement in alanine aminotransfer</td>
<td>20 obesity-related liver abnormalities children</td>
<td>[105]</td>
</tr>
<tr>
<td>L. johnsonii BS15</td>
<td>Effective in preventing NAFLD</td>
<td>HFD-induced NAFLD in mice</td>
<td>[78]</td>
</tr>
<tr>
<td>L. reuteri GMNL-263</td>
<td>Ameliorating hepatic steatosis</td>
<td>High-fructose diet fed rats</td>
<td>[79]</td>
</tr>
<tr>
<td>L. gasseri BNR17</td>
<td>Inhibiting increases in body and adipocyte tissue weight</td>
<td>High-sucrose diet-induced obese mice</td>
<td>[80]</td>
</tr>
<tr>
<td>3 Lactobacillus strains</td>
<td>Reducing serum TC, TG and low-density lipoprotein cholesterol</td>
<td>HFD fed rats</td>
<td>[166]</td>
</tr>
<tr>
<td>L. acidophilus NC FM</td>
<td>Inflammatory markers and the systemic inflammatory response were unaffected</td>
<td>45 males with T2DM</td>
<td>[111]</td>
</tr>
<tr>
<td>L. acidophilus</td>
<td>No changes in serum lipids</td>
<td>80 patients with elevated cholesterols</td>
<td>[113]</td>
</tr>
<tr>
<td>Bifidobacterium (Bif)</td>
<td>Ameliorating visceral fat accumulation and insulin sensitivity</td>
<td>HFD fed rats</td>
<td>[84]</td>
</tr>
<tr>
<td></td>
<td>Attenuating hepatic fat accumulation</td>
<td>HFD-induced NAFLD in rats</td>
<td>[86]</td>
</tr>
<tr>
<td></td>
<td>Reducing body and fat weights, blood serum levels (TC, HDL-C, LDL-C, TG, AST, ALT, and lipase levels)</td>
<td>HFD induced obesity rats</td>
<td>[167]</td>
</tr>
<tr>
<td>Probiotic</td>
<td>Reducing serum cholesterol, TG, and insulin resistance</td>
<td>HFD fed mice</td>
<td>[85]</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>------------------------------------------------------</td>
<td>--------------------</td>
<td>------</td>
</tr>
<tr>
<td>B.pseudocatenulatum CECT 7765</td>
<td>Reducing body weight gain, liver steatosis and cholesterol and TG concentrations</td>
<td>HFD induced obesity mice</td>
<td>[168]</td>
</tr>
<tr>
<td>Bacteroides uniformis CECT 7771</td>
<td>Limiting oxidative and inflammatory liver damage</td>
<td>HFD fed young rats</td>
<td>[92]</td>
</tr>
<tr>
<td></td>
<td>Reducing hepatic total fatty acid content and ALT levels.</td>
<td>HFD-induced NAFLD in mice</td>
<td>[93]</td>
</tr>
<tr>
<td></td>
<td>Improvements in steatosis and insulin resistance</td>
<td>HFD fed mice</td>
<td>[94]</td>
</tr>
<tr>
<td>VSL#</td>
<td>Modulating liver fibrosis but don't protecting from inflammation and steatosis in NASH.</td>
<td>MCD diet-induced NASH in mice.</td>
<td>[95]</td>
</tr>
<tr>
<td></td>
<td>Improving the degree of liver disease in children</td>
<td>44 Obese children with NAFLD</td>
<td>[104]</td>
</tr>
<tr>
<td></td>
<td>Improving plasma levels of lipid peroxidation markers: MDA, 4-HNE.</td>
<td>22 patients with NAFLD + 20 patients with AC</td>
<td>[169]</td>
</tr>
<tr>
<td></td>
<td>Experiencing a significant increase in liver fat; no significant differences in any of the blood assays or clinical parameters</td>
<td>4 patients with NAFLD</td>
<td>[110]</td>
</tr>
<tr>
<td></td>
<td>Improving NAFLD</td>
<td>HFD-induced NAFLD in rats</td>
<td>[96]</td>
</tr>
<tr>
<td></td>
<td>Delaying the progression of NAFLD via LPS/TLR4 signaling</td>
<td>HSHF diet-induced NAFLD in rats</td>
<td>[97]</td>
</tr>
<tr>
<td></td>
<td>Improving NAFLD pathogenesis and steatosis</td>
<td>High fat and sucrose diet (HFSD)-induced NAFLD in rats</td>
<td>[170]</td>
</tr>
<tr>
<td></td>
<td>Influencing protein expression and decreasing steatohepatitis</td>
<td>MCD diet-induced NASH in rats</td>
<td>[99]</td>
</tr>
<tr>
<td></td>
<td>Reducing obesity-related biomarkers and modulating the microbial community</td>
<td>Obese mice</td>
<td>[100]</td>
</tr>
<tr>
<td></td>
<td>Modulating gut microbiota and up-regulated genes related to fatty acid oxidation in both the liver and adipose tissue</td>
<td>HFD-induced obese mice</td>
<td>[98]</td>
</tr>
<tr>
<td></td>
<td>Improving liver aminotransferases levels</td>
<td>30 patients with NAFLD</td>
<td>[106]</td>
</tr>
<tr>
<td>Probiotic mixtures</td>
<td>Decreasing levels of ALT and AST and improving pediatric NAFLD</td>
<td>64 obese children with NAFLD</td>
<td>[171]</td>
</tr>
<tr>
<td>Interventions</td>
<td>Main effects</td>
<td>Experimental Models</td>
<td>Ref.</td>
</tr>
<tr>
<td>------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>--------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Oligofructose (OFS)</td>
<td>Exhibiting a lower LPS and cytokines, and decreasing hepatic expression of inflammatory and oxidative stress markers</td>
<td>Obese and diabetic mice</td>
<td>[119]</td>
</tr>
<tr>
<td></td>
<td>Decreasing serum ALT, AST and insulin level</td>
<td>Patients with NASH</td>
<td>[118]</td>
</tr>
<tr>
<td>Prebiotic</td>
<td>Restoring normal gastrointestinal microflora and intestinal epithelial barrier function, and decreasing steatohepatitis</td>
<td>MCD diet-induced NASH in mice.</td>
<td>[120]</td>
</tr>
</tbody>
</table>

**Table 2.** Gut microbiota-targeted therapies of NAFLD with prebiotics
### Table 3. Gut microbiota-targeted therapies of NAFLD with synbiotics

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Main effects</th>
<th>Experimental Models</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synbiotic</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L. paracasei B21060 + arabinogalactan + FOS</td>
<td>Lessening NAFLD progression, preserving gut barrier integrity and reducing the severity of liver injury and IR</td>
<td>HFD-induced NAFLD in rats</td>
<td>[137]</td>
</tr>
<tr>
<td>Seven probiotics + OFS</td>
<td>Improving NAFLD and decreasing levels of ALT and AST</td>
<td>52 patients with NAFLD</td>
<td>[141]</td>
</tr>
<tr>
<td>B. longum + FOS</td>
<td>Reductions in TNF-a, serum AST levels, serum endotoxin, steatosis, and the NASH activity index</td>
<td>66 patients with NASH</td>
<td>[142]</td>
</tr>
<tr>
<td>Dietary fiber + L. reuteri</td>
<td>Improving NAFLD and reducing serum levels of most of the inflammatory mediators</td>
<td>50 lean patients with NAFLD</td>
<td>[143]</td>
</tr>
</tbody>
</table>
Seven probiotics + FOS  |  Protecting against NAFLD progression and improving steatosis  |  80 NAFLD patients  |  [144]

Table 4. Gut microbiota-targeted therapies of NAFLD other approaches

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Main effects</th>
<th>Experimental Models</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibiotic</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cidomycin</td>
<td>Lowering serum levels of ALT, AST and TNF-α and alleviating the severity of NASH</td>
<td>Rats with NASH</td>
<td>[149]</td>
</tr>
<tr>
<td>Vancomycin+Neomycin+Metronidazole+Ampicillin</td>
<td>Adjusting gut microecology and alleviating the lesions of NAFLD</td>
<td>HFD-induced NAFLD in rats</td>
<td>[175]</td>
</tr>
<tr>
<td>Rifaximin</td>
<td>Improving NAFLD and reducing endotoxin and IL-10 levels</td>
<td>42 patients with NAFLD</td>
<td>[150]</td>
</tr>
<tr>
<td><strong>Herbal medicine or natural active ingredient</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2, 3, 5, 4’-tetrahydroxystilbene-2-O-β-D-glucoside (TSG)</td>
<td>Reversing NAFLD and reducing FFA accumulation, and increasing the protein expression of ZO-1 and occludin</td>
<td>HFD-induced NAFLD in rats</td>
<td>[160]</td>
</tr>
<tr>
<td>Resveratrol</td>
<td>Reducing blood glucose and lipid levels, and lowering both body and visceral adipose weights</td>
<td>HFD fed mice</td>
<td>[162]</td>
</tr>
<tr>
<td>Qushi Huayu Fang</td>
<td>Reducing body weight, TG and free fatty acids, alleviating hepatic steatosis</td>
<td>HFD-induced NAFLD in rats</td>
<td>[163]</td>
</tr>
<tr>
<td>Daesiho-tang (DSHT)</td>
<td>Enhancing the hepatic anti-oxidative mechanism, decreasing hepatic lipid synthesis, and promoting the regulatory T cell inducing microbiota in the gut</td>
<td>HFD-induced NAFLD in rats</td>
<td>[164]</td>
</tr>
<tr>
<td>Gegen Qinlian Decoction (GQD)</td>
<td>Ameliorating body weight gain, body fat, decreasing TC and TG</td>
<td>HFD fed obese mice</td>
<td>[165]</td>
</tr>
<tr>
<td></td>
<td>Alleviating T2D, increasing the amounts of beneficial bacteria</td>
<td>187 patients with type 2 diabetes (T2D)</td>
<td>[176]</td>
</tr>
</tbody>
</table>

4. Conclusion and perspective
Currently, gut microbiota has been recognized as a critical factor contributing to the development of NAFLD and the gut microbial-related mechanisms have also been well elucidated. As a result, the strategy of gut microbiota-targeted therapy on NAFLD is highly valued in the context of accumulating benefits of gut microbial modulation by using probiotics, prebiotics, synbiotics, antibiotics and herbal medicines. Although many experimental reports were exciting, discrepant results were also observed in the clinic. Therefore, the clinical efficacy of gut microbiota-targeted therapies on NAFLD still need to be confirmed with large-scale and well-organized RCT studies. The main factors contributing to the variation of therapeutic outcomes in the clinic include differences in bacterial activity of probiotics or due to the diversified dysbiosis among NAFLD patients. In this sense, probiotics with mixed bacteria such as VSL#3 are more prospective than those with individual type of bacteria. Meanwhile, the gut microbiota-related efficacy of natural components from herbal medicines or TCM formula itself highlighted the great potential of seeking novel medicines from TCM because some TCMs showed their effects by nourishing “good” bacteria and suppressing “bad” ones. Currently, 16S rDNA-based sequencing is still the major approach for most gut microbiota-involved studies because it is relatively affordable and applicable for most laboratories. Although 16S rDNA sequencing can provide general description on the structural differences of microbiome between samples, especially on the genus level, it is usually frustrating when information of specific bacteria species is heavily wanted. Consequently, metagenomics will be more applicable for figuring out specific bacterial species that may contribute to the disease development or therapeutic efficacy, as well as the involved microbial functions.

In summary, gut microbiota-targeted therapies on diseases are still in infancy. Nevertheless, we envision that more gut microbiota-targeted therapies will be tested in the context of accumulation of therapeutic evidence and advances in elucidation of gut microbial-related mechanisms in diseases, as well as the technological innovation of gut microbiome analysis.

Acknowledgments:
Dr. Houkai Li was funded by National Natural Science Foundation of China (No. 81673662), The Program for Professor of Special Appointment (Eastern Scholar) and Shuguang Scholar (16SG36) at Shanghai Institutions of Higher Learning from Shanghai Municipal Education Commission.

Author Contributions: Junli Ma retrieved all the references and drafted the manuscript, Qihang Zhou helped in the references retrieving. Houkai Li designed the manuscript and made revision of the text.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix

Search strategy
- The main source of material was pubmed, and the search keywords used were as follows: “gut microbiota”, “gut flora”, “nonalcoholic fatty liver disease (NAFLD)”, “nonalcoholic steatohepatitis (NASH)”, “steatosis”, “probiotic”, “prebiotic”, “antibiotic”, “herbal medicince”;
- Selected papers have no language restrictions;
- Most of the papers selected were published during the past 10 years;
- References of some identified papers were further searched for related papers to cover this topic as completely as possible.

References


Effects of Lactobacillus plantarum MA2 isolated from Tibet kefir on lipid metabolism and intestinal microflora of rats fed on high-cholesterol diet. *Appl Microbiol Biotechnol* 2009, 84, 341-7; DOI: 10.1007/s00253-009-2012-x.

Lactobacillus plantarum NCU116 improves liver function, oxidative stress and lipid metabolism in rats with high fat diet induced non-alcoholic fatty liver disease. *Food Funct* 2014, 5, 3216-23; DOI: 10.1039/c4fo00549j.

Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed rats. *Nutr Metab (Lond)* 2013, 10, 35; DOI: 10.1186/1743-7075-10-35.


85. Cano, P.G.; Santacruz, A.; Trejo, F.M.; Sanz, Y., Bifidobacterium CECT 7765 improves metabolic and immunological alterations associated with obesity in high-fat diet-fed mice. Obesity (Silver Spring) 2013, 21, 2310-21; DOI: 10.1002/oby.20330.

86. Xu, R.Y.; Wan, Y.P.; Fang, Q.Y.; Lu, W.; Cai, W., Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr 2012, 50, 72-7; DOI: 10.3164/jcbn.11-38.


